Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2022 Filed Mar 1, 2022 21:02 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 13,688 | $50.64 | $693,160.32 |
DisclosureSEC source: 0001225208-22-003665 · doc4.xml · nonDerivative · entry 3 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,998 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 21:02 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 7,511 | $47.72 | $358,424.92 |
DisclosureSEC source: 0001225208-22-003665 · doc4.xml · nonDerivative · entry 2 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,686 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 25, 2022. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 21:02 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionCommon Stock | 29,317 | $25.60 | $750,515.20 |
DisclosureSEC source: 0001225208-22-003665 · doc4.xml · nonDerivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 21:03 UTC |
McDermott MichaelExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 12,340 | $0.00 Strike: $25.60 | $0.00 |
DisclosureSEC source: 0001225208-22-003666 · doc4.xml · derivative · entry 5 McDermott Michael · CIK 0001902464 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,340 shares Expires 2022-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 21:03 UTC |
McDermott MichaelExecutive Vice President
|
Tax withholdingCommon Stock | 5,761 | $50.64 | $291,737.04 |
DisclosureSEC source: 0001225208-22-003666 · doc4.xml · nonDerivative · entry 3 McDermott Michael · CIK 0001902464 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,397 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 21:03 UTC |
McDermott MichaelExecutive Vice President
|
Tax withholdingCommon Stock | 2,372 | $47.72 | $113,191.84 |
DisclosureSEC source: 0001225208-22-003666 · doc4.xml · nonDerivative · entry 2 McDermott Michael · CIK 0001902464 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,158 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 25, 2022. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 21:03 UTC |
McDermott MichaelExecutive Vice President
|
Exercise / conversionCommon Stock | 12,340 | $25.60 | $315,904.00 |
DisclosureSEC source: 0001225208-22-003666 · doc4.xml · nonDerivative · entry 1 McDermott Michael · CIK 0001902464 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 21:03 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 77,709 | $0.00 Strike: $25.60 | $0.00 |
DisclosureSEC source: 0001225208-22-003667 · doc4.xml · derivative · entry 5 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 77,709 shares Expires 2022-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 21:03 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 36,282 | $50.64 | $1,837,320.48 |
DisclosureSEC source: 0001225208-22-003667 · doc4.xml · nonDerivative · entry 3 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,076 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 21:03 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 21,149 | $47.72 | $1,009,230.28 |
DisclosureSEC source: 0001225208-22-003667 · doc4.xml · nonDerivative · entry 2 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,358 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 25, 2022. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 21:03 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Exercise / conversionCommon Stock | 77,709 | $25.60 | $1,989,350.40 |
DisclosureSEC source: 0001225208-22-003667 · doc4.xml · nonDerivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 21:03 UTC |
Carapezzi William R JRExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 21,193 | $0.00 Strike: $25.60 | $0.00 |
DisclosureSEC source: 0001225208-22-003668 · doc4.xml · derivative · entry 6 Carapezzi William R JR · CIK 0001295078 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,193 shares Expires 2022-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 21:03 UTC |
Carapezzi William R JRExecutive Vice President
|
Tax withholdingCommon Stock | 9,895 | $50.64 | $501,082.80 |
DisclosureSEC source: 0001225208-22-003668 · doc4.xml · nonDerivative · entry 3 Carapezzi William R JR · CIK 0001295078 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,849 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 21:03 UTC |
Carapezzi William R JRExecutive Vice President
|
Tax withholdingCommon Stock | 4,619 | $47.72 | $220,418.68 |
DisclosureSEC source: 0001225208-22-003668 · doc4.xml · nonDerivative · entry 2 Carapezzi William R JR · CIK 0001295078 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,744 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 25, 2022. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 21:03 UTC |
Carapezzi William R JRExecutive Vice President
|
Exercise / conversionCommon Stock | 21,193 | $25.60 | $542,540.80 |
DisclosureSEC source: 0001225208-22-003668 · doc4.xml · nonDerivative · entry 1 Carapezzi William R JR · CIK 0001295078 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 22:55 UTC |
SUSMAN SALLYExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 63,580 | $0.00 Strike: $25.60 | $0.00 |
DisclosureSEC source: 0001225208-22-003724 · doc4.xml · derivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63,580 shares Expires 2022-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 22:55 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 29,685 | $50.64 | $1,503,248.40 |
DisclosureSEC source: 0001225208-22-003724 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,450 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 22:55 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 18,745 | $47.72 | $894,511.40 |
DisclosureSEC source: 0001225208-22-003724 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,135 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 25, 2022. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 22:55 UTC |
SUSMAN SALLYExecutive Vice President
|
Exercise / conversionCommon Stock | 63,580 | $25.60 | $1,627,648.00 |
DisclosureSEC source: 0001225208-22-003724 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 22:55 UTC |
DAMELIO FRANK AExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 127,160 | $0.00 Strike: $25.60 | $0.00 |
DisclosureSEC source: 0001225208-22-003723 · doc4.xml · derivative · entry 4 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 127,160 shares Expires 2022-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 22:55 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 59,370 | $50.64 | $3,006,496.80 |
DisclosureSEC source: 0001225208-22-003723 · doc4.xml · nonDerivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,941 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 22:55 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 34,607 | $47.72 | $1,651,446.04 |
DisclosureSEC source: 0001225208-22-003723 · doc4.xml · nonDerivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,311 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 25, 2022. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 22:55 UTC |
DAMELIO FRANK AExecutive Vice President
|
Exercise / conversionCommon Stock | 127,160 | $25.60 | $3,255,296.00 |
DisclosureSEC source: 0001225208-22-003723 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:06 UTC |
Carapezzi William R JRExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 20,073 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003459 · doc4.xml · derivative · entry 7 Carapezzi William R JR · CIK 0001295078 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,073 Underlying: Common Stock · 20,073 shares Expires 2029-02-24 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:06 UTC |
Carapezzi William R JRExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 22,823 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003459 · doc4.xml · derivative · entry 6 Carapezzi William R JR · CIK 0001295078 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,823 Underlying: Common Stock · 22,823 shares Expires 2027-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:06 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 362,427 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003460 · doc4.xml · derivative · entry 4 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,427 Underlying: Common Stock · 362,427 shares Expires 2029-02-24 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:06 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 412,081 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003460 · doc4.xml · derivative · entry 3 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,081 Underlying: Common Stock · 412,081 shares Expires 2027-02-24 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:43 UTC |
MALIK AAMIRExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 74,344 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003464 · doc4.xml · derivative · entry 2 MALIK AAMIR · CIK 0001881510 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,344 Underlying: Common Stock · 74,344 shares Expires 2029-02-24 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:43 UTC |
MALIK AAMIRExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 84,529 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003464 · doc4.xml · derivative · entry 1 MALIK AAMIR · CIK 0001881510 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,529 Underlying: Common Stock · 84,529 shares Expires 2027-02-24 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:43 UTC |
Fonseca LidiaExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 33,455 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003463 · doc4.xml · derivative · entry 2 Fonseca Lidia · CIK 0001454944 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,455 Underlying: Common Stock · 33,455 shares Expires 2029-02-24 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:43 UTC |
Fonseca LidiaExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 38,038 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003463 · doc4.xml · derivative · entry 1 Fonseca Lidia · CIK 0001454944 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,038 Underlying: Common Stock · 38,038 shares Expires 2027-02-24 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:46 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantStock Appreciation Rights · Derivative | 10,222 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003465 · doc4.xml · derivative · entry 7 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,222 Underlying: Common Stock · 10,222 shares Expires 2029-02-24 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:46 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantStock Appreciation Rights · Derivative | 11,623 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003465 · doc4.xml · derivative · entry 6 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,623 Underlying: Common Stock · 11,623 shares Expires 2027-02-24 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:46 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantCommon Stock | 2,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003465 · doc4.xml · nonDerivative · entry 4 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,407 F5 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:04 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 111,516 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003466 · doc4.xml · derivative · entry 6 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,516 Underlying: Common Stock · 111,516 shares Expires 2029-02-24 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:04 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 126,794 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003466 · doc4.xml · derivative · entry 5 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,794 Underlying: Common Stock · 126,794 shares Expires 2027-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:10 UTC |
Hwang AngelaGroup President
|
GrantStock Appreciation Rights · Derivative | 83,637 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003467 · doc4.xml · derivative · entry 8 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,637 Underlying: Common Stock · 83,637 shares Expires 2029-02-24 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:10 UTC |
Hwang AngelaGroup President
|
GrantStock Appreciation Rights · Derivative | 95,095 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003467 · doc4.xml · derivative · entry 7 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,095 Underlying: Common Stock · 95,095 shares Expires 2027-02-24 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:17 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 20,073 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003468 · doc4.xml · derivative · entry 7 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,073 Underlying: Common Stock · 20,073 shares Expires 2029-02-24 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:17 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 22,823 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003468 · doc4.xml · derivative · entry 6 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,823 Underlying: Common Stock · 22,823 shares Expires 2027-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:20 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 55,758 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003469 · doc4.xml · derivative · entry 7 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,758 Underlying: Common Stock · 55,758 shares Expires 2029-02-24 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:20 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 63,397 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003469 · doc4.xml · derivative · entry 6 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,397 Underlying: Common Stock · 63,397 shares Expires 2027-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:23 UTC |
McDermott MichaelExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 30,109 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003470 · doc4.xml · derivative · entry 6 McDermott Michael · CIK 0001902464 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,109 Underlying: Common Stock · 30,109 shares Expires 2029-02-24 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:23 UTC |
McDermott MichaelExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 34,234 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003470 · doc4.xml · derivative · entry 5 McDermott Michael · CIK 0001902464 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,234 Underlying: Common Stock · 34,234 shares Expires 2027-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:27 UTC |
SAHNI PAYALExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 37,172 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003471 · doc4.xml · derivative · entry 7 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,172 Underlying: Common Stock · 37,172 shares Expires 2029-02-24 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:27 UTC |
SAHNI PAYALExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 42,265 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003471 · doc4.xml · derivative · entry 6 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,265 Underlying: Common Stock · 42,265 shares Expires 2027-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:29 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 35,313 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003472 · doc4.xml · derivative · entry 7 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,313 Underlying: Common Stock · 35,313 shares Expires 2029-02-24 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:29 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 40,151 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003472 · doc4.xml · derivative · entry 6 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,151 Underlying: Common Stock · 40,151 shares Expires 2027-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:40 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 111,516 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003473 · doc4.xml · derivative · entry 4 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,516 Underlying: Common Stock · 111,516 shares Expires 2029-02-24 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:40 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 126,794 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003473 · doc4.xml · derivative · entry 3 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,794 Underlying: Common Stock · 126,794 shares Expires 2027-02-24 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.